RVTY revvity.com: תחזית צמיחת רווח נקי למניה לשנה הבאה

Revvity, Inc. (RVTY) focuses on high-margin biomedicine, implementing AI for drug discovery and gene therapy. The earnings per share growth projection for the next fiscal year shows that the parameter value is 9.80. Efficiency is maintained by outsourcing component production and logistics to external partners, while narrow technological specialization protects the company's market position from price competition.

Revvity, Inc. (RVTY) generates revenue through the supply of high-tech diagnostic systems and genomics reagents. This metric is calculated as the percentage change in expected earnings per share (EPS) between the current and the following fiscal year. This price action reflects market expectations regarding the monetization of innovations and the scaling of equipment sales. By analyzing the current consensus EPS growth forecast for the coming year, an investor can assess the business model's resilience to market volatility.